Exabis Library
Welcome to the e-CCO Library!
P0606: The efficacy of upadacitinib in Intestinal Behçet's Disease refractory to anti-TNF-α therapy in a retrospective study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0607: Opportunistic infections in patients with inflammatory bowel disease under advanced drug therapy. Real-word experience of 8 years from a medium-volume center in Cordobax7x7x7 Argentina.
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0608: Safety of guselkumab in Inflammatory Bowel Disease up to 1 year: Integrated safety analysis of phase 2 and 3 studies in Crohn’s Disease and Ulcerative Colitis
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0609: Real-world short and long-term effectiveness of risankizumab in refractory Crohn’s disease: RISANCROHN study from the ENEIDA Registry
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P060: A2B adenosine receptor deficiency ameliorates chronic murine Crohn’s-like-ileitis.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P060: Alterations of brain structure in Crohn’s disease with extraintestinal manifestations
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P060: Post-inflammatory visceral pain induced by DNBS: Preclinical features for novel therapeutics
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P060: Restoration of occludin and claudin-1 expression in patients with Crohn's disease receiving anti-TNF treatment.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P060: Role of innate lymphoid cells in the chronic colitis under anti-il-17a therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P060: The protective effect of necrosis inhibition on acute murine colitis induced by dextran sulphate sodium
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P060: Unravelling the microbial-derived metabolic alterations in a T-bet-/- x RAG2-/- mouse colitis model
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P061 The molecular landscape of perianal fistula in Crohn’s disease: opportunities for new therapeutic approaches
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P0610: Comparison of endoscopic remission and MRI defined remission using the simplified MaRIA score at week 48 from the PROFILE trial
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0611: Effectiveness comparisons between tofacitinibx7x7x7 filgotinib and upadacitinib in ulcerative colitis: results from the JAKARTA real-world evidence multicenter study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0612: Postoperative outcomes in tofacitinib-treated patients with acute severe ulcerative colitis undergoing total abdominal colectomy
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0613: Obesity is associated with inferior treatment outcomes in inflammatory bowel disease: a nationwide Dutch registry study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0614: Positive association of inflammatory bowel disease service research activity and adult patient-reported quality of care in the United Kingdom
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0615: Effectiveness and Safety Analysis of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0616: ViT-based deep learning and unsupervised clustering analysis in Crohn’s Disease based on body composition to identify distinct phenogroups and predict the effectiveness of anti-TNF therapy
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0617: Feasibility and safety of endoscopic submucosal dissection in inflammatory bowel disease (ESDEUR-IBD): an interim analysis of European retrospective study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM